Anti-cancer development based on RNA Platform technology Core competence to meet diverse unmet medical needs
Mechanism of RNA replacement enzyme
![]() |
|
---|
Hepatocellular toxicity after injection of RZ-001: AST and ALT levels on days 15 and 29 after single intravenous injection of RZ-001 into normal mice
AST and ALT levels of 0.5x10^10 and 1x10^10 VP-injected groups were observed to be at a level similar to those of a PBS-injected group.
Pro-drug, GCV, was administered for 10 days after injection of RZ-001.
AST and ALT levels of 0.5x10^10 and 1x10^10 VP-injected groups were observed to be at a level similar to those of a PBS-injected group.
In vivo anti-cancer efficacies of hit and RZ-001: Higher anti-cancer efficacy than hit in Xenograft liver metastasis HCC animal model